BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 22842983)

  • 1. Serum and glucocorticoid-regulated kinase 1 (SGK1) activation in breast cancer: requirement for mTORC1 activity associates with ER-alpha expression.
    Hall BA; Kim TY; Skor MN; Conzen SD
    Breast Cancer Res Treat; 2012 Sep; 135(2):469-79. PubMed ID: 22842983
    [TBL] [Abstract][Full Text] [Related]  

  • 2. mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1).
    García-Martínez JM; Alessi DR
    Biochem J; 2008 Dec; 416(3):375-85. PubMed ID: 18925875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro.
    Jordan NJ; Dutkowski CM; Barrow D; Mottram HJ; Hutcheson IR; Nicholson RI; Guichard SM; Gee JM
    Breast Cancer Res; 2014 Jan; 16(1):R12. PubMed ID: 24457069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. microRNA regulation of mammalian target of rapamycin expression and activity controls estrogen receptor function and RAD001 sensitivity.
    Martin EC; Rhodes LV; Elliott S; Krebs AE; Nephew KP; Flemington EK; Collins-Burow BM; Burow ME
    Mol Cancer; 2014 Oct; 13():229. PubMed ID: 25283550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The mechanistic target for rapamycin pathway is related to the phosphorylation score for estrogen receptor-α in human breast tumors in vivo.
    Shrivastav A; Bruce M; Jaksic D; Bader T; Seekallu S; Penner C; Nugent Z; Watson P; Murphy L
    Breast Cancer Res; 2014 May; 16(3):R49. PubMed ID: 24887419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The mTOR pathway controls cell proliferation by regulating the FoxO3a transcription factor via SGK1 kinase.
    Mori S; Nada S; Kimura H; Tajima S; Takahashi Y; Kitamura A; Oneyama C; Okada M
    PLoS One; 2014; 9(2):e88891. PubMed ID: 24558442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin upregulates the expression of epithelial sodium channel in vitro and in a mouse model of acute lung injury: role of mTORC2/SGK1 pathway.
    He J; Qi D; Wang DX; Deng W; Ye Y; Feng LH; Zhu T; Zhao Y; Zhang CR
    Exp Cell Res; 2015 Feb; 331(1):164-175. PubMed ID: 25265063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heregulin controls ERα and HER2 signaling in mammospheres of ERα-positive breast cancer cells and interferes with the efficacy of molecular targeted therapy.
    Fukui F; Hayashi SI; Yamaguchi Y
    J Steroid Biochem Mol Biol; 2020 Jul; 201():105698. PubMed ID: 32404282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer.
    Elkabets M; Vora S; Juric D; Morse N; Mino-Kenudson M; Muranen T; Tao J; Campos AB; Rodon J; Ibrahim YH; Serra V; Rodrik-Outmezguine V; Hazra S; Singh S; Kim P; Quadt C; Liu M; Huang A; Rosen N; Engelman JA; Scaltriti M; Baselga J
    Sci Transl Med; 2013 Jul; 5(196):196ra99. PubMed ID: 23903756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. mTOR complex-2 activates ENaC by phosphorylating SGK1.
    Lu M; Wang J; Jones KT; Ives HE; Feldman ME; Yao LJ; Shokat KM; Ashrafi K; Pearce D
    J Am Soc Nephrol; 2010 May; 21(5):811-8. PubMed ID: 20338997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphoproteome Analysis Reveals Estrogen-ER Pathway as a Modulator of mTOR Activity Via DEPTOR.
    Cuesta R; Gritsenko MA; Petyuk VA; Shukla AK; Tsai CF; Liu T; McDermott JE; Holz MK
    Mol Cell Proteomics; 2019 Aug; 18(8):1607-1618. PubMed ID: 31189691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevated SGK1 predicts resistance of breast cancer cells to Akt inhibitors.
    Sommer EM; Dry H; Cross D; Guichard S; Davies BR; Alessi DR
    Biochem J; 2013 Jun; 452(3):499-508. PubMed ID: 23581296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potentiation of Growth Inhibitory Responses of the mTOR Inhibitor Everolimus by Dual mTORC1/2 Inhibitors in Cultured Breast Cancer Cell Lines.
    Leung EY; Askarian-Amiri M; Finlay GJ; Rewcastle GW; Baguley BC
    PLoS One; 2015; 10(7):e0131400. PubMed ID: 26148118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cryptotanshinone inhibition of mammalian target of rapamycin pathway is dependent on oestrogen receptor alpha in breast cancer.
    Pan Y; Shi J; Ni W; Liu Y; Wang S; Wang X; Wei Z; Wang A; Chen W; Lu Y
    J Cell Mol Med; 2017 Sep; 21(9):2129-2139. PubMed ID: 28272775
    [TBL] [Abstract][Full Text] [Related]  

  • 15. mTORC1/C2 and pan-HDAC inhibitors synergistically impair breast cancer growth by convergent AKT and polysome inhibiting mechanisms.
    Wilson-Edell KA; Yevtushenko MA; Rothschild DE; Rogers AN; Benz CC
    Breast Cancer Res Treat; 2014 Apr; 144(2):287-298. PubMed ID: 24562770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PDK1-SGK1 Signaling Sustains AKT-Independent mTORC1 Activation and Confers Resistance to PI3Kα Inhibition.
    Castel P; Ellis H; Bago R; Toska E; Razavi P; Carmona FJ; Kannan S; Verma CS; Dickler M; Chandarlapaty S; Brogi E; Alessi DR; Baselga J; Scaltriti M
    Cancer Cell; 2016 Aug; 30(2):229-242. PubMed ID: 27451907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current development of the second generation of mTOR inhibitors as anticancer agents.
    Zhou HY; Huang SL
    Chin J Cancer; 2012 Jan; 31(1):8-18. PubMed ID: 22059905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional Role of mTORC2 versus Integrin-Linked Kinase in Mediating Ser473-Akt Phosphorylation in PTEN-Negative Prostate and Breast Cancer Cell Lines.
    Lee SL; Chou CC; Chuang HC; Hsu EC; Chiu PC; Kulp SK; Byrd JC; Chen CS
    PLoS One; 2013; 8(6):e67149. PubMed ID: 23840605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness and molecular interactions of the clinically active mTORC1 inhibitor everolimus in combination with tamoxifen or letrozole in vitro and in vivo.
    Martin LA; Pancholi S; Farmer I; Guest S; Ribas R; Weigel MT; Thornhill AM; Ghazoui Z; A'Hern R; Evans DB; Lane HA; Johnston SR; Dowsett M
    Breast Cancer Res; 2012 Oct; 14(5):R132. PubMed ID: 23075476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. mTORC1 directly phosphorylates and activates ERα upon estrogen stimulation.
    Alayev A; Salamon RS; Berger SM; Schwartz NS; Cuesta R; Snyder RB; Holz MK
    Oncogene; 2016 Jul; 35(27):3535-43. PubMed ID: 26522726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.